關於 Assertio Therapeutics, Inc.
Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As of 2019, Assertio markets three products approved by the FDA: Gralise, Cambia, and Zipsor.
Source: Wikipedia
總部251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US
成立時間2018
狀態營運中
專利1 項專利
GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF CNS DISORDERSEP2326310B1 · 2019
法律資訊
| 法定名稱 | Assertio Therapeutics, Inc. |
|---|---|
| LEI | 549300L2A9NTF1JVDP20在 GLEIF 上查看 ↗ |
| 登記地址 | 251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US |
| 狀態 | 營運中 |
來源: GLEIF · 更新於 2026年10月16日
聯絡方式與連結
地點
251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US
這是你的公司嗎?
免費認領此頁面,即可新增標誌、產品、照片與職缺,並回覆評論。
認領此頁面